MedinCell will publish its annual results on June 26, 2023 (April 2022 – March 2023)
Due to operational imperatives, the publication of the annual results for the fiscal year ended March 31, 2023, initially scheduled for June 13, has been postponed to June 26, 2023. MedinCell will hold a videoconference on the same day for its shareholders and of the financial community.
About MedinCell
MedinCell is an innovative pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas – from development to commercialization – by combining its proprietary BEPO® technology (licensed to Teva as SteadyTeq™) with principles active ingredients already known and marketed. Through the controlled and prolonged release of the active pharmaceutical ingredient, MedinCell makes medical treatments more effective, thanks in particular to better compliance and a reduction in the quantity of medication required.